SCHEMBL566074

SCHEMBL566074

Cc1cc(O)cc(C(=O)O)c1Br

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.48
ACHE P22303 1/20 0.48
MYC P01106 2/20 0.44
PTPN1 P18031 1/20 0.44
CA12 O43570 3/20 0.42
CA1 P00915 3/20 0.42
CA2 P00918 3/20 0.42
CA7 P43166 3/20 0.42
CA9 Q16790 3/20 0.42
CA14 Q9ULX7 3/20 0.42
ALOX5 P09917 1/20 0.42
PTGS2 P35354 1/20 0.42
HCAR1 Q9BXC0 1/20 0.41
HMGB1 P09429 1/20 0.40
CXCL12 P48061 1/20 0.40
NR4A1 P22736 1/20 0.40
ALDH1A1 P00352 3/20 0.39
KDM4E B2RXH2 2/20 0.39
HPGD P15428 2/20 0.39
HSD17B10 Q99714 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5351288 0.81 AKR1C3 (0.50) MYCPTGS2NR4A1KDM4EHPGD
SCHEMBL14940473 0.81 KDM4E (0.59) MYCHCAR1NR4A1ALDH1A1KDM4E
SCHEMBL15201876 0.79 HMGB1 (0.44) CYP3A4MYCPTPN1HMGB1CXCL12
SCHEMBL27300557 0.79 TPMT (0.46) MYCCA12CA1CA2CA7
SCHEMBL1812602 0.79 ALDH1A1 (0.48) CYP3A4MYCCA1CA2NR4A1
SCHEMBL23599863 0.79 CYP3A4 (0.53) CYP3A4ACHEMYCCA12CA1
SCHEMBL38891 0.78 HMGB1 (0.62) CYP3A4ACHEMYCPTPN1CA12
SCHEMBL89590 0.78 CYP3A4 (0.52) CYP3A4ACHEMYCPTPN1CA12
SCHEMBL8763536 0.78 CA1 (0.50) CYP3A4ACHEPTPN1CA12CA1
SCHEMBL1252263 0.78 MYC (0.39) MYCPTPN1HMGB1CXCL12NR4A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9499570-B2 Boron containing small molecules ANACOR PHARMACEUTICALS, INC. (US) 2016-11-22 US disclosed
US-20150376210-A1 BORON-CONTAINING SMALL MOLECULES ANACOR PHARMACEUTICALS, LLC 2015-12-31 US disclosed
US-9145429-B2 Boron-containing small molecules ANACOR PHARMACEUTICALS, INC. (US) 2015-09-29 US disclosed
US-20140200198-A1 BORON-CONTAINING SMALL MOLECULES ANACOR PHARMACEUTICALS, INC. (US) 2014-07-17 US disclosed
US-8716478-B2 Boron-containing small molecules ANACOR PHARMACEUTICALS, INC. (US) 2014-05-06 US disclosed
US-20120035132-A1 BORON-CONTAINING SMALL MOLECULES ANACOR PHARMACEUTICALS, INC. (US) 2012-02-09 US disclosed
WO-2011094450-A1 BORON-CONTAINING SMALL MOLECULES ANACOR PHARMACEUTICALS, INC (US) 2011-08-04 WO disclosed
EP-2321296-A1 SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF Bayer Schering Pharma Aktiengesellschaft (DE) 2011-05-18 EP disclosed
US-20100099681-A1 SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-04-22 US disclosed
WO-2010020363-A1 SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140200198-A1 BORON-CONTAINING SMALL MOLECULES BTD, BCL6B, BBOX1 CYP3A4 2408/4885ACHE 830/4885MYC 1792/4885
US-20120035132-A1 BORON-CONTAINING SMALL MOLECULES BTD, BCL6B, BBOX1 CYP3A4 2408/4885ACHE 830/4885MYC 1792/4885
US-20150376210-A1 BORON-CONTAINING SMALL MOLECULES BTD, BCL6B, BBOX1 CYP3A4 2408/4885ACHE 830/4885MYC 1792/4885
US-20100099681-A1 SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF CYP3A5, ABAT, TPMT CYP3A4 16/4885ACHE 1351/4885MYC 2568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.